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Abstract 
Background: Recent studies have linked non‑alcoholic fatty liver disease (NAFLD) to a reduced bone mineral density 
(BMD). We aimed to detect the quantitative association of liver fat content (LFC) and serum alanine aminotransferase 
(ALT) with BMD in a middle‑aged and elderly Chinese population.
Methods: The lumbar spine, hip and whole body BMDs were measured using dual‑energy x‑ray absorptiometry 
(Lunar iDXA, GE Healthcare) in 1659 Chinese (755 men and 1028 postmenopausal women) from Shanghai Changfeng 
community. Liver fat content was quantified via an ultrasound quantitative method. Multivariate linear regression 
analyses were carried out to determine the independent association of LFC and serum ALT with BMD and bone meta‑
bolic biomarkers. We also attempted to investigate the synergistic association between LFC and ALT as risk factors for 
bone mineral loss in Chinese.
Results: Subjects with higher LFC had significantly lower BMD at all skeletal sites. Univariate correlation analy‑
sis showed that both LFC and ALT were inversely associated with BMD at the spine (r = −0.116, P < 0.001 and 
r = −0.102, P = 0.005), hip (r = −0.095, P = 0.014 and r = −0.075, P = 0.041) and whole body sites (r = −0.134, 
P < 0.001 and r = −0.164, P < 0.001) in men. After confounders were controlled for, LFC and ALT remained associated 
with BMD and bone formation biomarkers in men, but not postmenopausal women. When both NAFLD and eleva‑
tion of ALT were present, there was a significant synergistic worsening of the BMDs at all bone sites.
Conclusions: Liver fat content and serum ALT were inversely correlated with BMD in middle‑aged and elderly men. 
The underlying mechanism might relate to a reduction in osteoblast activity. Elevation of the hepatotoxic biomarker 
ALT may indicate high risk for osteoporosis in patients with NAFLD.
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Background
As the incidence of obesity reaches the epidemic level 
worldwide, non-alcoholic fatty liver disease (NAFLD) is 
also becoming a main public health concern [1, 2]. Once 
loaded with excessive triglyceride, liver could secrete 
a serial of pro/anti- inflammatory cytokines to disrupt 
the normal function of distant organs [3]. Several stud-
ies have demonstrated the associations of NAFLD with 
type 2 diabetes, chronic kidney disease, and cardiovascu-
lar diseases [4–6]. The cross-talks of NAFLD with other 
organs and its role in the pathogenesis of metabolic dis-
eases are attracting extensive attention [7, 8].
Osteoporosis, characterized by decrease of body 
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health problem in the aging society [9]. Previous lab-
oratory studies have shown a complex network of 
interaction among the adipose tissue, liver and bone 
[10, 11]. In parallel to the experimental studies, sev-
eral recent case–control studies reported a significant 
decrease of BMD [12–14] and increase of osteoporotic 
fracture risk [15] in subjects with NAFLD. However, 
most studies in adults used common ultrasonography 
to diagnose NAFLD, which provided no information 
on the severity of liver steatosis. The associations of 
liver fat content (LFC) and hepatotoxic biomarker ala-
nine aminotransferase (ALT) with BMD have not been 
fully studied, and the mechanisms underlying the asso-
ciation between NAFLD and bone mineral loss are still 
not clear.
In the current study, we measure the LFCs by a ultra-
sound quantitative method [16] in a large-scale middle-
aged and elderly Chinese population, and investigated 
the association of LFC and ALT with BMD. Our study 
aimed to provide new insights into the relation between 
NAFLD and age-related bone mineral loss.
Methods
Study subjects
The present study consisted of 2224 participants of 
Shanghai Changfeng Study, a community-based pro-
spective cohort study of chronic diseases in a mid-
dle-aged and elderly Chinese population, who were 
consecutively recruited from May 2010 to June 2011 
[17]. Among the initial 2224 participants, 441 were 
excluded from study enrollment because they were indi-
viduals with viral hepatitis B or C (86 persons), renal 
failure (75 persons), history of thyroid dysfunction (17 
persons), excessive alcohol consumption  ≥10  g/d for 
women and ≥20 g/d for men (143 persons) [18], with-
out BMD data (120 persons), and 124 premenopausal 
women were also excluded. Finally, a total of 1659 com-
munity participants (755 men and 904 postmenopausal 
women; age range 46–93 years; mean 63.2 ± 10.3 years) 
were included in the study. This study was approved by 
the Research Ethics Committee of the Shanghai Health 
Bureau, and all participants provided written informed 
consent.
DXA measurements of BMD and body composition analysis
BMD (g/cm2) at the lumbar spine (L1–L4), total hips and 
the whole body region and the body fat masses at the 
whole body, trunk, and limbs sites were measured using 
dual-energy x-ray absorptiometry (Lunar iDXA, GE 
Healthcare). Body fat distribution was represented by the 
ratio of trunk to appendicular fat mass (trunk-appendic-
ular fat ratio) [19]. A single, trained technician at a single 
clinical center carried out all measurements.
Quantitative ultrasonography
Hepatic ultrasound examination was performed in all 
patients by an ultrasonographist (who was unaware of 
the clinical details of the participants). The ultrasound 
images were taken by a GE Logiq P5 scanner (GE Health-
care, Milwaukee, WI, USA), analyzed using NIH image 
software (ImageJ 1.41o, National Institutes of Health, 
Bethesda, MD, USA) and standardized using a tissue-
mimicking phantom (Model 057; Computerized Imaging 
Reference Systems, Norfolk, VA, USA) to correct for the 
instrument differences. As detailed in our previous work 
[16], all the instrument settings, including “gain”, “depth”, 
and “time-gain compensation”, were calibrated using the 
tissue-mimicking phantom before measurement. The 
ultrasound images with both liver and right kidney clearly 
visualized in the sagittal liver/kidney view and the right 
liver lobe in right intercostal view at anterior axilla line 
were captured under the ultrasound machine and trans-
ferred to a personal computer installed with NIH image 
software. In the sagittal liver/right kidney view, a region 
of interest (ROI) of 1.5 × 1.5 cm (1296 pixels) in the liver 
parenchyma and another ROI of 0.5 × 0.5 cm (144 pixels) 
in the right renal cortex at the same depth was selected. 
In right intercostal view at anterior axilla line, two ROIs 
of 1.5 × 1.5 cm (1296 pixels) were also selected in liver 
homogeneous regions near the liver anterior margin 
(depth 4–6  cm) and the liver posterior margin, respec-
tively. The echo intensity within the ROIs was measured, 
as well as the linear distance between the liver anterior 
and posterior ROIs. Then the LFC was obtained using the 
automatic calculator (Additional file 1) based on the fol-
lowing equation: LFC (%) = 62.592 × ultrasound hepatic/
renal ratio + 168.076 × hepatic attenuation rate −27.863 
[16]. The LFC by ultrasound quantitative method showed 
excellent correlation and agreement with that by proton 
magnetic resonance spectroscopy previously (r  =  0.89, 
P < 0.001), and this method has been used to investigate 
the associations of LFC with carotid atherosclerosis and 
diabetes previously [20, 21]. The subjects were defined 
as NAFLD if their LFCs by quantitative ultrasonogra-
phy ≥9.15 % [16, 21].
Anthropometric and biochemical measurements
Each participant underwent a clinical examination 
that consisted of an interview by a trained investigator, 
anthropometric measurements and serum biochemi-
cal examinations. Information regarding demograph-
ics, lifestyle, medical history and current medication 
was obtained through interview and questionnaires. 
The questionnaire regarding alcohol intake included 
items about the type of alcoholic beverage consumed, 
the frequency of alcohol consumption on a weekly basis 
and the usual amount of daily alcohol consumption. 
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Participants were classified as non- or light-drinkers 
or as excessive drinkers when their average alcohol 
consumption was  <140  g/week for men (<70  g/week 
for women) or  >140  g/week for men (>70  g/week for 
women) [18], respectively. Smoking status was defined 
as non-smoker or smoker. Standing height and body-
weight were measured without shoes or outer clothing. 
The body mass index (BMI) was calculated as weight 
(kg) divided by height squared (m2). Blood samples were 
obtained after a fasting period of at least 12  h. Total 
cholesterol (TC), high-density lipoprotein cholesterol 
(HDL-c), low-density lipoprotein cholesterol (LDL-c), 
triglycerides (TG), creatine, uric acid and liver enzymes 
were measured using a model 7600 automated bio-ana-
lyzer (Hitachi, Tokyo, Japan). The fasting blood glucose 
(FBG) and 2 h post load glucose levels following a 75 g 
oral glucose challenge for non-diabetics were measured 
using the glucose oxidase method. Serum osteocalcin, 
25-hydroxyvitamin D [25(OH)D] and β-isomerized form 
carboxy-terminal telopeptide of type I collagen (β-CTx) 
were measured using electrochemiluminescence immu-
noassay. The glomerular filtration rate (eGFR) was cal-
culated using the Modification of Diet in Renal Disease 
(MDRD) Study formula [22].
Statistical analysis
All statistical analyses were performed using SPSS soft-
ware version 15.0 (SPSS, Chicago, IL, USA). Kolmogo-
rov–Smirnov Test was used for test of normality. Data 
were presented as mean ± SD, except for skewed varia-
bles, which were presented as median with the interquar-
tile range (25–75 %) given in parentheses. Anova or the 
Kruskal–Wallis test was used for intergroup comparisons 
of continuous data, whereas the Chi squared test was 
used for comparisons of categorical variables. We strati-
fied all analyses by sex [23], and the skewed variables 
were log transformed to approximate normal distribution 
before analyses. Correlations of BMD with LFC, serum 
ALT as well as other metabolic parameters were inves-
tigated using the linear correlation analysis after adjust-
ment for age and body weight [24–26]. Multiple linear 
regression models were used to examine the independ-
ent associations of LFC with spine, hip and whole body 
BMD, adjusting for age, body weight, total body fat per-
centage (BF %), trunk-appendicular fat ratio and the vari-
ables that displayed significant associations with BMD in 
the univariate correlation analysis. We also calculated the 
sample size for the multivariate linear regression analysis, 
and a sample size of 1184 would allow for the detection 
of small effects (r2 = 0.02) in multiple regression analysis 
with all covariates in the analysis with 2-tailed alpha of 
0.05 and power of 0.80 [27].
To determine if ALT levels and LFC had synergis-
tic effects on age-related bone mineral loss, the average 
BMDs were compared across three groups: (1) subjects 
without NAFLD; (2) subjects with NAFLD and normal 
ALT (≤40 IU/L); (3) subjects with NAFLD and increased 
ALT level (>40  IU/L). All P values reported were two-
tailed and P < 0.05 was considered significant.
Results
Clinical characteristics of the study population
The prevalence of NAFLD, metabolic syndrome and 
diabetes in the study population was 31.8, 29.2 and 
18.7  %, respectively. The median LFC for the 1659 
subjects was 4.9  % (interquartile range, 2.1–11.5  %). 
Subjects were stratified into four subgroups accord-
ing to the quartiles of LFC, and subjects with higher 
LFC were younger, more obese and had lower BMD at 
all bone sites. Higher LFC was in parallel with higher 
BF %, trunk fat mass, appendicular fat mass and trunk-
appendicular fat ratio, and correlated with higher liver 
enzymes, blood pressure, fbg and unfavourable lipid 
profiles (All P < 0.05). Serum levels of osteocalcin were 
also significantly decreased in subjects with elevation 
of LFC (Table 1).
Association of LFC and serum ALT level with BMD
After age and body weight were controlled for, LFC was 
negatively associated with BMD in both men and women 
(Fig.  1). These associations were significant at lumbar 
spine (r = −0.116, P < 0.001), hip (r = −0.095, P = 0.014) 
and whole body site (r = −0.134, P < 0.001) in men. In 
postmenopausal women, significant negative associations 
were also observed at the whole-body site (r = −0.107, 
P = 0.002) and the lumbar spine (r = −0.093, P = 0.008).
Serum ALT is commonly measured clinically as a bio-
marker for liver injury. In men, there were also inverse 
correlations of serum ALT with BMD at the whole 
body (r = −0.164, P < 0.001), lumbar spine (r = −0.102, 
P = 0.005), and hip (r = −0.075, P = 0.041). In postmen-
opausal women, ALT showed no association with spine 
and whole body BMD, and only marginal significant 
association with hip BMD (r = 0.067, P = 0.046) (Fig. 2).
Association of body fat distribution and metabolic 
parameters with BMD
In parallel to the change of LFC, increased total BF % was 
also significantly associated with lower BMD at the hip 
(r  =  −0.082, P  =  0.025) and whole-body (r  =  −0.171, 
P < 0.001) in men, and BMD at all bone sites (r = −0.146 
to −0.265, All P  <  0.001) in women. Trunk-appendicu-
lar fat ratio represented the central distribution of body 
fat, and showed negative correlation with whole-body 
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Table 1 Demographic characteristics and metabolism and bone status of the study population
SBP systolic blood pressure, DBP diastolic blood pressure, ALT alanine aminotransferase, AST aspartate aminotransferase, GGT gamma-glutamyl transferase, Apo-A 
apolipoprotein A, Apo-B apolipoprotein B, FBG fasting blood glucose, PBG postprandial blood glucose, GFR glomerular filtration rate, BMD bone mineral density, 
25(OH)VitD 25-hydroxyvitamin D, β-CTx β-isomerized form carboxy-terminal telopeptide of type I collagen
a P < 0.05 compared with Q1
b P < 0.05 compared with Q2
c P < 0.05 compared with Q3
d Age and body weight were adjusted for before intergroup comparison
Total Liver fat content P value
Q1 Q2 Q3 Q4
Demographic
 Number (men/women) 1659 (755/904) 413 (192/221) 416 (194/222) 414 (185/229) 416 (184/232) 0.859
 Age (years) 62 (56–72) 63 (56–74) 64 (57–74) 61 (55–71)a,b 62 (55–70)a,b 0.005
 Alcohol drinking n (%) 128 (7.2 %) 30 (7.3 %) 29 (7.0 %) 36 (9.2 %) 30 (7.2 %) 0.606
 Cigarette smoking n (%) 340 (19.1 %) 76 (18.4 %) 85 (20.4 %) 90 (21.7 %) 84 (20.2 %) 0.694
 Height (cm) 161.4 ± 8.3 161.4 ± 8.0 161.0 ± 8.0 161.5 ± 8.4 161.8 ± 8.4 0.677
 Weight (kg) 63.4 ± 10.8 60.8 ± 9.4 60.8 ± 10.1 63.0 ± 10.7a,b 68.9 ± 10.7a,b,c <0.001
 BMI (kg/m2) 24.3 ± 3.3 23.3 ± 2.7 23.4 ± 3.0 24.1 ± 3.4a,b 26.3 ± 3.1a,b,c <0.001
Medication
 Calcium n (%) 215 (12.1 %) 57 (13.8 %) 51 (12.3 %) 43 (10.4 %) 4 9 (11.8 %) 0.508
 Vitamin D n (%) 92 (5.2 %) 28 (6.8 %) 19 (4.6 %) 15 (3.6 %) 22 (5.3 %) 0.206
 Bisphophonates n (%) 4 (0.2 %) 0 (0.0 %) 0 (0.0 %) 1 (0.2 %) 2 (0.5 %) 0.301
Metabolic parameters
 SBP (mmHg) 134 (123–150) 133 (121–147) 133 (121–148) 133 (122–149) 137 (128–153)a,b,c <0.001
 DBP (mmHg) 77 (70–83) 76 (69–83) 75 (68–82) 76 (69–83) 79 (73–85)a,b,c <0.001
 ALT (IU/L) 16 (12–22) 15 (12–19) 14 (11–19) 16 (12–21) 20 (14–28)a,b,c <0.001
 AST (IU/L) 20 (17–23) 20 (17–22) 19 (17–22) 19 (17–23) 20 (18–25)a,b,c 0.001
 GGT (IU/L) 24 (18–36) 21 (16–29) 21 (17–31) 24 (18–38)a,b 29 (21–42)a,b,c <0.001
 Triglyceride (mmol/L) 1.4 (1.1–2.1) 1.3 (1.0–1.7) 1.3 (1.0–1.8) 1.5 (1.1–2.1)a,b 1.8 (1.3–2.5)a,b,c <0.001
 Cholesterol (mmol/L) 5.12 ± 0.95 5.13 ± 0.93 5.02 ± 0.91 5.16 ± 0.94b 5.16 ± 1.00b 0.130
 HDL‑c (mmol/L) 1.4 (1.1–1.6) 1.5 (1.2–1.7) 1.4 (1.2–1.7) 1.3 (1.1–1.6)a,b 1.2 (1.1–1.4)a,b,c <0.001
 LDL‑c (mmol/L) 2.95 ± 0.81 3.00 ± 0.79 2.87 ± 0.76a 2.97 ± 0.81 2.94 ± 0.86 0.133
 Apo‑A (U/L) 1.4 (1.3–1.6) 1.52 (1.32–1.70) 1.44 (1.26–1.66)a 1.41 (1.24–1.62)a 1.37 (1.21–1.56)a,b,c <0.001
 Apo‑B (U/L) 1.02 ± 0.22 1.00 ± 0.21 0.98 ± 0.23 1.03 ± 0.21 1.06 ± 0.22a,b,c <0.001
 FBG (mmol/L) 5.1 (4.8–5.7) 5.0 (4.7–5.6) 5.1 (4.8–5.6) 5.1 (4.8–5.6) 5.3 (4.9–6.0)a,b,c <0.001
 PBG (mmol/L) 6.8 (5.6–8.8) 6.3 (5.3–7.9) 6.4 (5.3–7.9) 6.8 (5.6–9.2)a,b 7.8 (6.6–10.2)a,b,c <0.001
 eGFR (mL/min) 95 (84–108) 95 (83–110) 94 (83–106) 95 (85–110) 94 (83–108) 0.134
Body composition
 Body fat percentage (%) 34.2 (28.9–39.1) 32.7 (27.6–38.2) 32.9 (27.8–37.7) 34.3 (28.8–39.0)a,b 36.4 (31.6–41.2)a,b,c <0.001
 Trunk fat (kg) 11.6 (9.3–14.0) 10.5 (8.5–12.7) 10.6 (8.2–12.8) 11.5 (9.5–13.9)a,b 13.8 (11.6–16.2)a,b,c <0.001
 Appendicular fat (kg) 7.5 (6.2–9.1) 7.0 (5.8–8.6) 7.2 (5.9–8.6) 7.4 (6.1–8.9)a 8.4 (7.0–10.0)a,b,c <0.001
 Trunk‑Appendicular fat ratio 1.50 (1.29–1.72) 1.44 (1.24–1.63) 1.40 (1.20–1.64) 1.54 (1.32–1.76)a,b 1.62 (1.45–1.83)a,b,c <0.001
 Liver fat content (%) 4.9 (2.1–11.5) 0.5 (0.0–1.4) 3.4 (2.8–4.1)a 7.5 (6.1–9.3)a,b 16.6 (14.1–21.4)a,b,c <0.001
Bone status
 Spine BMD (g/cm2)d 1.0624 ± 0.1683 1.0715 ± 0.1703 1.0728 ± 0.1627 1.0693 ± 0.1708 1.0359 ± 0.1674a,b,c 0.004
 Hip BMD (g/cm2)d 0.8174 ± 0.1163 0.8216 ± 0.1180 0.8238 ± 0.1156 0.8199 ± 0.1166 0.8043 ± 0.1144a,b,c 0.066
 Whole‑body BMD (g/cm2)d 1.0708 ± 0.1151 1.0811 ± 0.1193 1.0785 ± 0.1069 1.0717 ± 0.1171 1.0516 ± 0.1149a,b,c <0.001
 Osteocalcin (ng/ml) 18.6 (14.4–23.5) 19.0 (14.6–23.8) 19.8 (15.0–24.2) 18.6 (14.2–24.1)b 17.4 (13.7–22.0)a,b,c <0.001
 25(OH)Vit D (nmol/L) 44.5 (34.6–58.3) 46.5 (35.0–59.5) 42.9 (33.3–56.4) 43.7 (34.7–58.4) 44.9 (34.6–58.8) 0.339
 ALP (U/L) 73 (62–87) 73 (62–87) 73 (62–87) 73 (61–86) 76 (64–90) 0.227
 β‑CTx (ng/ml) 0.40 (0.26–0.58) 0.39 (0.29–0.56) 0.40 (0.27–0.61) 0.41 (0.25–0.56) 0.40 (0.26–0.59) 0.500
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(r  =  −0.122, P  <  0.001) and hip BMD (r  =  −0.069, 
P  =  0.027) in postmenopausal women and whole-body 
BMD (r = −0.078, P = 0.034) in men (Table 2).
Significant associations between BMD and NAFLD-
related metabolic parameters were also found in both 
men and postmenopausal women. BMDs at specific bone 
site were significantly associated with systolic blood pres-
sure (SBP), serum TG and TC in men, and SBP, FBG and 
uric acid in postmenopausal women after adjustment for 
age and body weight. Cigarette smoking is also related to 
decreased BMD at all bone sites in men (Table 2).
Independent contribution of LFC and ALT to variability 
in BMD and bone metabolic biomarkers
In multiple regression analysis, after adjustment for age 
and body weight (Table  3,4 model 1), LFC and serum 
Fig. 1 The associations between LFC and BMDs at the whole body (a, b), lumbar spine (c, d) and total hip (e, f) sites in middle‑aged and elderly 
men (panels on the left) and postmenopausal women (panels on the right)
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ALT were significantly correlated with BMD at the lum-
bar spine (Stdβ = −0.116, P = 0.003 and Stdβ = −0.102, 
P  =  0.005), total hip (Stdβ  =  −0.097, P  =  0.014 and 
Stdβ  =  −0.075, P  =  0.041) and whole-body BMD 
(Stdβ = −0.134, P < 0.001 and Stdβ = −0.164, P < 0.001) 
in men. LFC was also negatively associated with 
whole-body (Stdβ  =  −0.107, P  =  0.002) and spine 
(Stdβ  =  −0.093, P  =  0.008) BMD in postmenopausal 
women. Parameter estimates of these correlations 
remained significant after successively adjusting for use 
of osteoporotic drug, alcohol drinking, cigarette smok-
ing, and metabolic parameters such as SBP, TG, TC, FBG, 
uric acid in both genders (model 2) and then in addi-
tion total BF % and trunk-appendicular fat ratio in men 
(model 3). In model 4, the significant negative correlation 
between LFC and BMD remained at all bone sites after 
Fig. 2 The associations between serum ALT level and BMDs at the whole body (a, b), lumbar spine (c, d) and total hip (e, f) sites in middle‑aged 
and elderly men (panels on the left) and postmenopausal women (panels on the right)
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additional adjustment for serum 25(OH)D, osteocalcin 
and β-CTx level (model 4). In multiple regression mod-
els, LFC and ALT was also negatively associated with 
serum osteocalcin in men (models 1–3).
Interactions between ALT and LFC as risk factors for bone 
mineral loss in men
Compared to individuals with normal LFC, NAFLD 
patients had significantly lower BMD at the lumbar spine 
and whole body sites (Fig. 3a, b). When both NAFLD and 
elevation of ALT level were present, there was a syner-
gistic worsening of the BMD at all bone sites, as shown 
in Fig. 3. Serum osteocalcin was also decreased with ele-
vated serum ALT and presence of NAFLD.
Discussion
In the current study, we provide the epidemiological 
evidence showing that LFC and serum ALT have inde-
pendent and inverse relationships with BMD at the 
lumbar spine, hip and whole body sites in middle-aged 
and elderly Chinese men. Both LFC and ALT were asso-
ciated with serum osteocalcin, a biochemical marker for 
the activity of osteoblasts in patients with NAFLD [28]. 
According to our results, elevation of the hepatotoxic 
biomarker ALT may indicate high risk for osteoporosis in 
patients with NAFLD.
Visceral fat accumulation has been related to decreased 
BMD [29, 30]. In accordance with the association 
between visceral fat and BMD, metabolic syndrome, 
featured by central obesity and insulin resistance, was 
demonstrated as a risk factor for developing osteoporo-
sis clinically [31]. NAFLD is thought to be the hepatic 
manifestation of metabolic syndrome [1]. Therefore, a 
relationship between NAFLD and osteoporosis has been 
assumed. Several recent observations of lower BMD in 
obese children and postmenopausal women with NAFLD 
were reported [12, 13]. In the current study, using the 
ultrasound quantitative method for LFC [16], we found 
Table 2 Association of bone mineral density with liver fat content and metabolic parameters
Age and body weight were adjusted
SBP systolic blood pressure, FBG fasting blood glucose, HDL-c high-density lipoprotein-cholesterol
Spine BMD Hip BMD Whole body BMD
r P r P r P
Men
 Cigerette smoking −0.186 <0.001 −0.095 0.009 −0.158 <0.001
 Alcohol drinking −0.004 0.914 −0.020 0.584 −0.043 0.241
 Liver fat content −0.116 <0.001 −0.095 0.014 −0.134 <0.001
 Body fat percentage 0.019 0.600 −0.082 0.025 −0.171 <0.001
 Trunk to appendicular fat ratio 0.058 0.119 0.005 0.884 −0.078 0.034
 SBP −0.178 <0.001 0.057 0.125 0.063 0.086
 FBG 0.070 0.058 0.041 0.264 −0.008 0.817
 Triglyceride −0.019 0.616 −0.030 0.418 −0.112 0.002
 Cholesterol −0.025 0.504 −0.126 0.001 −0.098 0.007
 HDL‑c 0.037 0.322 −0.026 0.476 0.048 0.196
 Uric acid 0.022 0.543 0.021 0.559 −0.007 0.842
 Anti‑osteoporotic drug 0.001 0.999 −0.015 0.679 −0.018 0.616
Postmenopausal women
 Cigerette smoking −0.064 0.057 −0.010 0.771 0.001 0.992
 Alcohol drinking −0.025 0.446 0.033 0.326 −0.013 0.700
 Liver fat content −0.093 0.008 −0.034 0.331 −0.107 0.002
 Body fat percentage −0.127 <0.001 −0.119 <0.001 −0.227 <0.001
 Trunk to appendicular fat ratio −0.069 0.027 −0.045 0.152 −0.112 <0.001
 SBP −0.099 0.003 −0.108 0.001 −0.163 <0.001
 FBG −0.067 0.046 −0.025 0.464 −0.107 0.001
 Triglyceride 0.000 0.999 0.001 0.994 −0.034 0.307
 Cholesterol −0.013 0.688 0.001 0.992 −0.010 0.764
 HDL‑c −0.042 0.206 −0.009 0.791 −0.004 0.911
 Uric acid 0.136 <0.001 0.080 0.045 0.105 0.002
 Anti‑osteoporotic drug 0.029 0.386 0.007 0.895 0.023 0.494
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LFC was negatively and independently associated with 
BMD in middle-aged and elderly Chinese. This finding 
remained after controlling for total BF % and its central 
distribution. Therefore, liver fat might play a role in the 
pathogenesis of osteoporosis independent of centrally 
located body fat.
The mechanisms underlying the relation between 
NAFLD and low BMD are still not clear. We measured 
bone metabolism biomarkers in subjects with NAFLD, 
and found that serum osteocalcin, a well-established 
biomarker for osteoblast acitivity [28], was signifi-
cantly decreased in male subjects with NAFLD, but the 
Table 3 Multiple linear regression analysis for the association between liver fat content (independent variable) and BMD 
and bone metabolic parameters (dependent variables) in different models
Model 1 included liver fat content, age and body weight
Model 2 included liver fat content, age, body weight, alcohol drinking, cigarrete smoking, anti-osteporotic drug use, SBP, FBG, triglyceride, cholesterol, and uric acid
Model 3 included liver fat content, age, body weight, alcohol drinking, cigarrete smoking, SBP, FBG, triglyceride, cholesterol, HDL-c,uric acid, body fat percentage, and 
trunk to appendicular fat ratio
Model 4 included same as model 3 plus serum 25(OH)D, osteocalcin, and β-CTx levels
Std β denotes standardized β coefficient, BMD bone mineral density, 25(OH)VitD 25-hydroxyvitamin D, β-CTx β-isomerized form carboxy-terminal telopeptide of type I 
collagen, SBP systolic blood pressure, FBG fasting blood glucose, HDL-c high-density lipoprotein-cholesterol
Model 1 Model 2 Model 3 Model 4
Std β P Std β P Std β P Std β P
Men
 Lumbar spine BMD −0.116 0.003 −0.111 0.003 −0.111 0.003 −0.123 0.001
 Hip BMD −0.095 0.014 −0.101 0.007 −0.092 0.017 −0.101 0.008
 Whole‑body BMD −0.134 <0.001 −0.122 0.001 −0.123 0.001 −0.130 <0.001
 25(OH)D −0.073 0.044 −0.027 0.457 −0.018 0.638 – –
 Osteocalcin −0.183 <0.001 −0.133 <0.001 −0.116 0.001 – –
 β‑CTx 0.014 0.715 0.015 0.694 0.023 0.560 – –
Postmenopausal women
 Lumbar spine BMD −0.093 0.008 −0.086 0.015 −0.056 0.116 −0.068 0.068
 Hip BMD −0.034 0.331 −0.044 0.215 −0.015 0.689 −0.029 0.429
 Whole‑body BMD −0.107 0.002 −0.072 0.041 −0.023 0.510 −0.041 0.224
 25(OH)D 0.027 0.410 0.034 0.332 0.044 0.223 – –
 Osteocalcin −0.060 0.099 −0.046 0.197 −0.025 0.498 – –
 β‑CTx −0.035 0.298 −0.029 0.384 −0.021 0.563 – –
Table 4 Multiple linear regression analysis for the association between ALT (independent variable) and BMD and bone 
metabolic parameters (dependent variables) in different models (Men)
Model 1 included liver fat content, age and body weight
Model 2 included liver fat content, age, body weight, alcohol drinking, cigarrete smoking, anti-osteporotic drug use, SBP, FBG, triglyceride, cholesterol, and uric acid
Model 3 included liver fat content, age, body weight, alcohol drinking, cigarrete smoking, SBP, FBG, triglyceride, cholesterol, HDL-c,uric acid, body fat percentage, and 
trunk to appendicular fat ratio
Model 4 included same as model 3 plus serum 25(OH)D, osteocalcin, andβ-CTx levels
Std β denotes standardized β coefficient, BMD bone mineral density, 25(OH)VitD 25-hydroxyvitamin D, β-CTx β-isomerized form carboxy-terminal telopeptide of type I 
collagen, SBP systolic blood pressure, FBG fasting blood glucose, HDL-c high-density lipoprotein-cholesterol
Model 1 Model 2 Model 3 Model 4
Std β P Std β P Std β P Std β P
Men
 Lumbar spine BMD −0.102 0.005 −0.120 0.001 −0.120 0.001 −0.142 <0.001
 Hip BMD −0.075 0.041 −0.062 0.105 −0.056 0.151 −0.073 0.046
 Whole‑body BMD −0.164 <0.001 −0.152 <0.001 −0.118 0.001 −0.143 <0.001
 25(OH)D 0.012 0.747 0.017 0.647 −0.018 0.638 – –
 Osteocalcin −0.093 0.012 −0.085 0.019 −0.102 0.006 – –
 β‑CTX 0.001 0.994 0.001 0.981 0.002 0.952 – –
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bone resorption markers (i.e., β-CTx) [32] remained 
unchanged. Therefore, the decrease of BMD in sub-
jects with NAFLD might be related to an inhibition of 
osteoblast activities. There have been several hypoth-
eses regarding pathogenesis of osteoporosis in NAFLD. 
Hepatic insulin resistance has been related to low cir-
culating osteocalcin, decreased bone formation and 
deficient numbers of osteoblasts [33], and might be 
responsible for lower osteocalcin level and BMD in the 
NAFLD patients. However, the associations between 
LFC and BMD at all bone sites still existed after adjusting 
for all components of metabolic syndrome as well as the 
total body fat mass, so a direct interaction between liver 
tissue and bone [11] may also contribute to the acceler-
ated bone loss in patients with NAFLD. As is shown pre-
viously, fat-infiltrated liver itself may produce a series 
of cytokines and other bone-influencing molecules, 
including TNFα, interleukin-6, interleukin-1 and Fetuin-
A [34], and these molecules could further inhibit activ-
ity of osteoblast and osteogenesis [35]. Several previous 
studies also reported that NAFLD was related to vitamin 
D metabolism [36]. Vitamin D exerts a significant effect 
on calcium and bone metabolism, and was converted to 
25(OH)D in the liver for its active form [37]. However, 
in our current study, 25(OH)D was not changed with 
increasing LFC. The inconsistency might be explained by 
the difference of liver function status. Most of NAFLD 
patients in our study had mild liver steatosis with nor-
mal liver enzyme levels, while the previous case–control 
study enrolled NAFLD patients mostly with elevated liver 
enzymes, who were more likely to have impaired func-
tion of vitamin D metabolism.
ALT is commonly measured clinically as a biomarker 
for hepatocellular injury. In the current study, ALT was 
Fig. 3 Comparison of average bone mineral density at lumbar spine, hip and whole body sites and serum osteocalcin level in subjects with normal 
LFC, NAFLD and ALT within the normal range, and NAFLD and ALT elevation. There was a synergistic decrease in BMDs and osteocalcin level in 
individuals with both NAFLD and ALT elevation
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also found to be associated with BMD in subjects with 
NAFLD. It has been demonstrated that ALT levels not 
only correlated with the severity of liver steatosis grades 
[38], but also associated with markers of systemic inflam-
mation (CRP) [39] and oxidative stress [40] in NAFLD 
patients. The mechanisms of inflammation and oxidative 
stress were involved in the pathogenesis of age-related 
bone loss [41, 42]. Therefore, ALT can be used as a clini-
cal biomarker for risk of osteoporosis in NAFLD patients.
We reported a relationship of LFC and serum ALT with 
BMD in middle-aged and elderly men, but not in women. 
The gender difference in the association between LFC 
and BMD has also been noticed in recent studies [14, 15]. 
The differences between men and women in features of 
age-related osteoporosis [43, 44], body fat deposition [45] 
and sex hormone levels could be potential explanations. 
However, we cannot deduce the mechanisms of the gen-
der difference in our current study, which need to be elu-
cidated further.
There are several limitations in this study. Firstly, the 
present study was a cross-sectional study, and did not 
permit the identification of causal relationships between 
LFC and BMD, which needs to be further evaluated 
in longitudinal studies. Secondly, in a study of our cur-
rent size, it was not possible to obtain liver biopsies to 
investigate the association of BMD with liver fibrosis 
or inflammation. Thirdly, the sex hormone levels of the 
community subjects were not measured, so the effect of 
estrogen deficiency may interfere with the association 
between LFC and BMD in postmenopausal women.
Conclusion
Osteoporosis is one of the major public health problems 
in the aging Chinese society. Our study has provided the 
epidemiological evidence that both LFC and hepatotoxic 
biomarker ALT were inversely correlated with BMD and 
biomarkers of bone formation in middle-aged and elderly 
Chinese men. Elevation of ALT, a traditional serum bio-
marker for hepatocellular injury, may indicate high risk 
for osteoporosis in patients with NAFLD.
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